Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.36 |
| ▸ | GCK | P35557 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960957 | 1.00 | PTGS2 (0.36) | PTGS2GCKPTGDR2ALOX5PDE4A | |
| SCHEMBL1960923 | 0.91 | GCK (0.35) | PTGS2GCK | |
| SCHEMBL1960924 | 0.91 | GCK (0.35) | PTGS2GCK | |
| SCHEMBL1962772 | 0.90 | PTGS2 (0.37) | PTGS2GCKGPR119 | |
| SCHEMBL1962775 | 0.90 | PTGS2 (0.37) | PTGS2GCKGPR119 | |
| SCHEMBL1960949 | 0.89 | HDAC3 (0.37) | PTGS2GCK | |
| SCHEMBL1960951 | 0.89 | HDAC3 (0.37) | PTGS2GCK | |
| SCHEMBL1961900 | 0.88 | HDAC3 (0.37) | PTGS2GCK | |
| SCHEMBL1961899 | 0.88 | HDAC3 (0.37) | PTGS2GCK | |
| SCHEMBL1961058 | 0.88 | PTGS2 (0.40) | PTGS2GCKGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | PTGS2 1580/4885GCK 1/4885PTGDR2 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.